Lepetegravir

Lepetegravir
Clinical data
Other names	GS-1720
Identifiers
	IUPAC name (10S,13R)-6-hydroxy-10,13-dimethyl-5,8-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-1,2,9-triazatricyclo[7.4.1.02,7]tetradeca-3,6,11-triene-4-carboxamide;
CAS Number	2808219-64-7;
PubChem CID	164590400;
ChemSpider	129698520;
UNII	U7N3Q737CA;
ChEMBL	ChEMBL5883239;
Chemical and physical data
Formula	C21H19F3N4O4
Molar mass	448.402 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@H]1C=C[C@H](N2CN1C(=O)C3=C(C(=O)C(=CN32)C(=O)NCC4=C(C=C(C=C4F)F)F)O)C;
	InChI InChI=InChI=1S/C21H19F3N4O4/c1-10-3-4-11(2)28-9-26(10)21(32)17-19(30)18(29)14(8-27(17)28)20(31)25-7-13-15(23)5-12(22)6-16(13)24/h3-6,8,10-11,30H,7,9H2,1-2H3,(H,25,31)/t10-,11+/m0/s1; Key:AFHGIULBHAXDDI-WDEREUQCSA-N;

Lepetegravir is an investigational new drug that is being developed by Gilead Sciences for the treatment of HIV-1 infection. It is a HIV integrase inhibitor.^[1]^[2]

References

↑ "Lepetegravir". AdisInsight. Springer Nature Switzerland AG. Retrieved 3 July 2026.
↑ Arens Y, Gulick RM (January 2025). "Future options for long-acting HIV treatment and prevention". Current Opinion in HIV and AIDS. 20 (1): 39–47. doi:10.1097/COH.0000000000000901. PMID 39560965.

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.